89.49
0.97%
+0.86
Biomarin Pharmaceutical Inc. stock is currently priced at $89.49, with a 24-hour trading volume of 1.21M.
It has seen a +0.97% increased in the last 24 hours and a +5.12% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $89.03 pivot point. If it approaches the $89.78 resistance level, significant changes may occur.
Biomarin Pharmaceutical Inc. Stock (BMRN) Financials Data
Biomarin Pharmaceutical Inc. (BMRN) Revenue 2024
BMRN reported a revenue (TTM) of $2.42 billion for the quarter ending December 31, 2023, a +15.42% rise year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Net Income 2024
BMRN net income (TTM) was $167.65 million for the quarter ending December 31, 2023, a +18.43% increase year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Cash Flow 2024
BMRN recorded a free cash flow (TTM) of $51.65 million for the quarter ending December 31, 2023, a +16.42% increase year-over-year.
Biomarin Pharmaceutical Inc. (BMRN) Earnings per Share 2024
BMRN earnings per share (TTM) was $0.88 for the quarter ending December 31, 2023, a +19.13% growth year-over-year.
Biomarin Pharmaceutical Inc. Stock (BMRN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BIENAIME JEAN JACQUES | Director |
Apr 12 '24 |
Sale |
91.26 |
20,000 |
1,825,200 |
474,994 |
BIENAIME JEAN JACQUES | Director |
Apr 11 '24 |
Option Exercise |
63.10 |
20,000 |
1,262,000 |
494,994 |
BIENAIME JEAN JACQUES | Director |
Apr 11 '24 |
Sale |
90.99 |
20,000 |
1,819,800 |
474,994 |
Burkhart Erin | GVP, Chief Accounting Officer |
Apr 10 '24 |
Sale |
90.00 |
2,286 |
205,740 |
16,156 |
Davis George Eric | EVP, Chief Legal Officer |
Mar 28 '24 |
Sale |
88.34 |
24,602 |
2,173,341 |
55,856 |
Slamon Dennis | Director |
Mar 18 '24 |
Option Exercise |
79.70 |
10,000 |
797,000 |
40,809 |
BIENAIME JEAN JACQUES | Director |
Mar 06 '24 |
Sale |
86.71 |
1,000 |
86,713 |
560,203 |
FUCHS HENRY J | President, Worldwide R&D |
Mar 05 '24 |
Sale |
85.18 |
35,341 |
3,010,396 |
212,117 |
Ajer Jeffrey Robert | EVP, Chief Commercial Officer |
Mar 05 '24 |
Sale |
87.07 |
4,000 |
348,280 |
94,047 |
BIENAIME JEAN JACQUES | Director |
Mar 05 '24 |
Sale |
85.51 |
1,000 |
85,510 |
561,203 |
Biomarin Pharmaceutical Inc. Stock (BMRN) Latest News
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks Investment Research
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
Zacks Investment Research
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Zacks Investment Research
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
About Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Cap:
|
Volume (24h):